BSE Live
Apr 20, 16:01Prev. Close
159.60
Open Price
160.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:56Prev. Close
159.29
Open Price
158.79
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
155.33 (399)
| Cash Flow of Kopran (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 51.95 | 67.54 | 36.07 | 81.78 | 83.34 | |
| Net CashFlow From Operating Activities | 41.94 | 43.26 | 34.02 | -33.48 | 59.95 | |
| Net Cash Used In Investing Activities | -56.43 | -43.55 | -12.65 | -84.42 | -24.41 | |
| Net Cash Used From Financing Activities | 25.87 | 0.99 | -19.84 | 122.82 | -34.57 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 11.38 | 0.69 | 1.53 | 4.93 | 0.97 | |
| Cash And Cash Equivalents Begin of Year | 8.09 | 7.40 | 5.87 | 0.94 | 0.83 | |
| Cash And Cash Equivalents End Of Year | 19.47 | 8.09 | 7.40 | 5.87 | 1.81 |
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth